Clinical Trial Update: Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of GSK2838232 in adults infected with HIV-1 has completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections
• Human Immunodeficiency Virus Infection

Drugs mentioned

• GSK2838232

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infection, Human Immunodeficiency Virus, HIV Infections | Phase 2 | Status: COMPLETED | Results posted: 2019-05-29